Background: Adult survivors of childhood cancer have been reported to have an increased risk of late sequels. A cluster of abnormalities that contribute to the metabolic syndrome may be expressed at a higher level and therefore result in an increased risk for diabetes mellitus and cardiovascular diseases.
During the last decades, the survival rate of childhood cancer has improved remarkably, resulting in an increasing number of survivors [1] . Some of these survivors are now 30 or even more years after treatment. Children who survive cancer are at risk of developing late effects, as treatment is intensive and therapy is administered in a growing and developing individual. Various studies investigated the risk of second malignancies, cardiac problems, pulmonary complications, impaired fertility, problems of offspring, osteoporosis and obesity in survivors of childhood cancer [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Mertens [13] found an increased standardised mortality ratio for cardiovascular diseases in survivors of several childhood malignancies. Obesity is a frequently reported late effect in long-term survivors of childhood acute lymphoblastic leukaemia (ALL), especially when treatment included cranial irradiation [3, 14] . In addition, in survivors of other malignancies obesity has been reported [15, 16] . Several studies described a range of disorders like dyslipidaemia, hypertension, hyperinsulinaemia, impaired glucose tolerance and insulin resistance in long-term survivors after treatment of various malignancies [17] [18] [19] . Together with obesity, these factors are in fact components of 'the metabolic syndrome'.
The metabolic syndrome was first described by Reaven in 1988 [20] . He found a clustering of symptoms, including insulin resistance, hyperinsulinaemia, glucose intolerance, elevated levels of triglycerides, a reduced high-density lipoprotein (HDL) level and hypertension, in patients and called this the Syndrome X. It was indicated to be an important risk factor for developing cardiovascular diseases and diabetes mellitus type II. Since then, many definitions of this metabolic syndrome were proposed by different organisations [21] [22] [23] [24] [25] [26] . Each definition contains at least the next components: insulin resistance or hyperglycaemia or hyperinsulinaemia, in combination with obesity, hypertension and dyslipidaemia. Other additional factors that are associated with the metabolic syndrome are a pro-inflammatory state, a pro-thrombotic state, hyperuricaemia, hyperleptinaemia and microalbuminuria. So far studies on the metabolic syndrome in large cohorts of childhood cancer survivors are not available. Therefore, we evaluated the metabolic syndrome in our cohort of childhood cancer survivors. Table 3 .
total cholesterol and HDL-cholesterol
Compared with controls, total cholesterol was significantly increased in females (mean SDS 0.39, P < 0.001), but not in males [mean SDS 0.09, not significant (ns)]. HDL was At least two of the following:
Blood pressure ‡140/90 mmHg or medication Obesity: body mass index ‡30 (kg/m 2 ) Self-reported prevalence of diabetes or medication Serum total cholesterol ‡5.2 mmol/l or medication original article Annals of Oncology significantly increased in males compared with controls (mean SDS 0.29, P = 0.009), but not in females (mean SDS 0.16, ns). Comparing cancer types, total cholesterol was increased in acute myeloid leukaemia (mean SDS 0.94, P = 0.001), bone tumour (mean SDS 0.60, P = 0.011) and malignant mesenchymal tumour (mean SDS 0.40, P = 0.035) survivors. HDL was increased in non-Hodgkin's lymphoma (mean SDS 0.48, P = 0.021) and Wilms' tumour survivors (mean SDS 0.47, P = 0.002) ( Table 4 ). No differences in total cholesterol or HDL were found between patients who received CRT or not (Tables  5 and 6 ). ALL survivors who received CRT had higher total cholesterol levels compared with ALL survivors who did not (mean SDS 0.38 versus mean SDS 20.05, P = 0.027), whereas their HDL levels did not differ.
blood pressure
Mean systolic blood pressure was significantly higher in males (mean SDS 0.80, P < 0.001) and in females (mean SDS 1.11, P < 0.001) as compared with controls. Diastolic blood pressure was significantly higher in females (mean SDS 0.31, P < 0.001), but lower in males (mean SDS 0.21, P < 0.001). Systolic blood pressure was increased in survivors of all cancer types, except for Langerhans cell histiocytosis (LCH). Diastolic blood pressure was decreased in ALL survivors (Table 4) . No differences in systolic or diastolic blood pressure were found between CRT and non-CRT groups (Tables 5 and 6 ). However, ALL survivors treated with CRT were more often hypertensive compared with ALL survivors not treated with CRT (22% versus 10%, P = 0.036). with survivors not treated with CRT, had a significantly higher BMI (mean SDS difference 0.46, P < 0.001) ( Table 5) . Male survivors treated with CRT were more often overweight (59% versus 28%, P = 0.001) and more often obese (13% versus 2.0%, P = 0.015). Female survivors treated with CRT were more often overweight (55% versus 27%, P = 0.004), but not more often obese (Table 6 ). Additionally, survivors treated with CRT more frequently had low IGF-1 levels compared with survivors not treated with CRT (29% versus 5%, P < 0.001).
Moreover, ALL survivors treated with CRT, compared with ALL survivors not treated with CRT, had a significantly increased BMI (mean SDS difference 0.34, P = 0.014). ALL survivors treated with CRT were more often overweight compared with ALL survivors not treated with CRT (59% versus 34%, P = 0.003), but not more often obese (12% versus 9%, ns). ALL survivors treated with CRT more frequently had low IGF-1 levels compared with ALL survivors not treated with CRT (32% versus 8%, P = 0.003).
diabetes mellitus
In our patient group, 3 of 500 (0.6%) survivors had selfreported diabetes mellitus. One of them was 19 years old, diagnosed with chronic myeloid leukaemia at the age of 1 year and treated with chemotherapy, radiotherapy and bone marrow transplantation. The other two were 24 and 29 years old, both survivors of Wilms' tumour. They were both treated with surgery and chemotherapy, the latter also with radiotherapy. None of the diabetic patients had received cranial irradiation or prednisone therapy. BMIs of these patients were, respectively, 18, 24 and 31 kg/m 2 . The prevalence of diabetes in the patients seemed to be the same as in the normal population (Table 6 ).
combining components of the metabolic syndrome
Scoring of components of the metabolic syndrome was carried out according to the definition of Haugnes et al. [30] (Table 2) , which indicates subjects with at least two components as positive. In 466 survivors, information on all required parameters was available; 13% (n = 59) of the survivors had at least two components (males 12% and females 14%) of the metabolic syndrome; 2% had three components and in only one person (0.2%) four components were determined. Of the 59 survivors with two or more components of the metabolic syndrome, 52 were younger than 40 years.
Prevalence of the metabolic syndrome was higher in male CRT patients than in male non-CRT patients (25% versus 7%, P = 0.003), but not in female CRT patients compared with female non-CRT patients (18% versus 12%, ns) ( Table 6 ). Prevalence of the metabolic syndrome was higher in ALL survivors treated with CRT compared with ALL survivors not treated with CRT (23% versus 7%, P = 0.011).
discussion
We found that long-term adult survivors of childhood cancer, especially those treated with CRT, are at increased risk of developing components of the metabolic syndrome. The present analysis of 500 adult survivors of childhood cancer provides information on the occurrence of components of the metabolic syndrome in long-term survivors of 11 types of Restricted to patients not treated with bone marrow transplantation and patients not treated with radiotherapy other than cranial. HDL, high-density lipoprotein-cholesterol; BMI, body mass index; non-CRT, survivors not treated with cranial irradiation; CRT, survivors treated with cranial irradiation; CI, confidence interval; SystBP, systolic blood pressure; DiastBP, diastolic blood pressure. Restricted to patients not treated with bone marrow transplantation and patients not treated with radiotherapy other than cranial. HDL, high-density lipoprotein-cholesterol; non-CRT, survivors not treated with cranial irradiation; CRT, survivors treated with cranial irradiation; ns, not significant; na, not available.
original article Annals of Oncology childhood cancer, using a large epidemiological control group. Although several childhood cancer survivor studies have also shown the possible relationship between treatment and an increased risk of developing risk factors contributing to the metabolic syndrome, studies have been limited by small sample sizes and lack of optimal comparison groups. Additionally, most studies assessed only one or some determinants of the metabolic syndrome instead of the full content of the syndrome or focused on only one type of cancer. Our study shows that total cholesterol levels were elevated in females, in contrast to in males. This was not due to increased HDL. Therefore, it seems likely that the increased cholesterol in females can be explained by low-density lipoproteins (LDLs) or very low-density lipoproteins. These lipoproteins are known to cause atherosclerosis and therefore increase the risk of cardiovascular diseases. Why male survivors have higher HDL levels, which may be advantageous, is unclear. Additionally, survivors of ALL treated with CRT had increased total cholesterol levels (mean SDS 0.38 versus mean SDS 20.05, P = 0.027) compared with their counterparts not treated with CRT. Dyslipidaemia has been reported in survivors of ALL [3, 14] , brain cancer [31] , stem-cell transplantation [19] and heterogeneous groups of survivors of childhood cancer [18, 32] . However, besides decreased HDL levels, elevated LDL levels and/or elevated triglyceride levels characterise dyslipidaemia. Unfortunately, LDL and triglycerides were not available in this survey. This indicates that the contribution of dyslipidaemia may even be higher than we indirectly observed by total cholesterol and HDL measurement.
In our study, we found increased systolic blood pressure both in men and women. Systolic blood pressure was increased after treatment of all types of malignancies, except for LCH (Table  4) . Systolic and diastolic blood pressures were both significantly correlated with BMI and hypertensive survivors were more often overweight than survivors with normal blood pressure. Additionally, ALL survivors treated with CRT were more often hypertensive than ALL survivors not treated with CRT, which might be explained by a relatively stronger correlation between systolic and diastolic blood pressure and BMI in this subgroup. A previous study did not find a significant difference in blood pressure between 50 survivors of childhood cancer (excluding brain cancer) at a median follow-up time of 13 years and controls. However, they found a higher systolic blood pressure in a risk group, which they defined by the combination of obesity, hyperinsulinaemia and low HDL levels [32] . Furthermore, hypertension has been reported in 13%-19% in studies that included 103 and 124 adult survivors of a variety of malignancies, respectively [17, 18] . It is unknown what determines the elevated blood pressure in survivors. Dysfunction of the endothelium has been hypothesised to be the initial step in the development of cardiovascular diseases. Chemotherapy agents like anthracyclines are known to damage the vascular endothelium. Additionally, radiotherapy could have a damaging effect on the endothelium.
We found BMI not to be increased significantly, neither in males nor females. As BMI is not representing the exact distribution of fat, it is possible that measuring abdominal obesity by measuring the waist circumference would have identified abdominal adiposity more accurately. This is illustrated by the fact that normal BMIs together with increased abdominal obesity have been reported in ALL survivors [3, 4] . It is advisable to measure waist circumference and lean body mass in future studies. The survivors treated with CRT had a significantly higher BMI compared with non-CRT survivors. Male and female survivors were more often overweight and males also more often obese compared with the normal population. Male ALL survivors treated with CRT were more often overweight than male ALL survivors not treated with CRT; however, they were not more often obese. Female ALL survivors treated with CRT were not more often overweight or obese. These results are in contrast to those of Oeffinger et al. [12] , who reported a higher incidence of obesity in female ALL survivors treated with CRT ‡20 Gy, than in males and normal controls. It should be noticed that Oeffinger et al. used self-reported BMI values, whereas we actually measured weight and height. Obesity has been reported frequently in survivors treated with CRT [4, 15, 32, 33] , in which growth hormone deficiency is indicated to play a causal role. Growth hormone deficiency may be not only caused by direct pituitary damage resulting from CRT but also by hypothalamic damage. Although a low IGF-1 level is a reasonable indicator of growth hormone deficiency, a normal IGF-1 will not rule out growth hormone deficiency. For this, a dynamic assessment of growth hormone is necessary. It should, however, be considered that these tests are more invasive for the survivors.
Only 3 of 500 survivors had diabetes, i.e. two survivors of Wilms' tumour and one survivor of chronic myeloid leukaemia. Insulin resistance, in which a given concentration of insulin is associated with a subnormal glucose response, has been described in adult survivors of several malignancies [3, 14, 18, 19, 32] . Therefore, it is important to investigate insulin resistance in the future in larger prospective cohorts, as well as parameters like pro-thrombotic and pro-inflammatory factors, hyperuricaemia, hyperleptinaemia and microalbuminuria, which are also reported to be associated with the occurrence of the metabolic syndrome.
Besides the size, the strength of the current study is the availability of the unique control cases of the epidemiological MORGEN study in The Netherlands. This enabled the comparison of BMI, total cholesterol and HDL, blood pressure and the prevalence of diabetes mellitus in childhood cancer survivors with the normal population. However, although the MORGEN study measured the single components of the metabolic syndrome, no direct estimation of the prevalence of the metabolic syndrome was provided. In our cohort, 59 (13%) survivors had the metabolic syndrome. Interestingly, 52 (12%) of these survivors were younger than 40 years. In several European countries, a prevalence of the metabolic syndrome varying between 7%-36% (male) and 5%-22% (female) aged 40-55 years has been described [24] . Studies in 20-to 40-yearold normal people are unfortunately not available. The fact that 12% of the survivors younger than 40 already met the criteria for the metabolic syndrome indicates that the metabolic syndrome may play an important role in our survivors. In the normal population, the prevalence of the metabolic syndrome increases with age [34] , indicating that this may reflect an emerging problem in the future. This indicates that screening
